Dong-Wan Kim

Associate Professor

Seoul National University Hospital

South Korea

Research Interests

Explore related searches

Professors in South Korea Professors in Cancer Biology Cancer Biology professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dong-Wan Kim is an Associate Professor at Seoul National University Hospital in South Korea. His research interests focus on non-small cell lung cancer and include recent studies on novel therapies and drug combinations for advanced and metastatic tumors. His significant contributions to the field include investigations into the efficacy of immunotherapies and targeted treatments in various lung cancer populations.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2020

Year:

2020

Collaborators (9)

Seokyung Hahn

Seoul National University College of Medicine

SOUTH KOREA

View details

Taiguang Jin

Head of Discovery Biology

BrightPath Biotherapeutics

UNITED STATES

View details

Tae Min Kim

Seoul National University Hospital

SOUTH KOREA

View details

Jorge Gomez

Mount Sinai Hospital

UNITED STATES

View details

Gwanghee Lee

SOUTH KOREA

View details

Thomas J George

University of Florida

UNITED STATES

View details

Dong Hyun Kim

Seoul National University College of Medicine

SOUTH KOREA

View details

Peter Grimison

The University of Sydney School of Medicine

AUSTRALIA

View details

ENRIQUETA FELIP

Head Thoracic Oncology Unit (After Competitive Exam)

Hospital Universitari Vall d'Hebron

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Dong-Wan Kim

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy

Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial

Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors

Transcriptomic Heterogeneity of EGFR-Mutant Non–Small Cell Lung Cancer Evolution Toward Small-Cell Lung Cancer

Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM)

A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19)

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions

Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study

Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301

Artificial intelligence‐powered spatial analysis of tumor‐infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: A single‐center, retrospective, longitudinal cohort study

BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell lines

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

Clinical Application of Next-Generation Sequencing–Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies

Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive‐stage disease small cell lung cancer: Results from a randomized controlled trial

Collaborators (9)

Seokyung Hahn

Taiguang Jin

Tae Min Kim

Jorge Gomez

Gwanghee Lee

Thomas J George

Dong Hyun Kim

Peter Grimison

ENRIQUETA FELIP

Make your next move.